圖片僅供參考

BAV199,215

Name: BAV199,215
Rating: 4.7 (12 reviews)

DIODE ARRAY GP 75V 160MA TO236AB

製造商
製造商。部分 #BAV199,215
包
資料表 BAV199,215 DataSheet
有現貨的8549

+BOM RFQ

100%原創；新

24小時準備發貨

365天保修

RFQ&；獲得更多折扣

規格

Part Status	Active
Diode Configuration	1 Pair Series Connection
Technology	Standard
Voltage - DC Reverse (Vr) (Max)	75 V
Current - Average Rectified (Io) (per Diode)	160mA (DC)
Voltage - Forward (Vf) (Max) @ If	1.25 V @ 150 mA
Speed	Small Signal =< 200mA (Io), Any Speed
Reverse Recovery Time (trr)	3 µs
Current - Reverse Leakage @ Vr	5 nA @ 75 V
Operating Temperature - Junction	150°C (Max)
Mounting Type	Surface Mount
Package / Case	TO-236-3, SC-59, SOT-23-3
Supplier Device Package	TO-236AB
Base Product Number	BAV199

概述

Description

BAV199 and BAV215 are investigational monoclonal antibodies being researched for their potential therapeutic applications, particularly in the treatment of various cancers. BAV199 is designed to target and inhibit a specific pathway involved in tumor growth and survival, while BAV215 may focus on enhancing the immune response against cancer cells.
Both antibodies are part of a broader effort to develop targeted therapies that minimize side effects compared to traditional chemotherapy. Clinical trials are crucial for evaluating their safety, efficacy, and optimal dosing regimens. Researchers aim to determine how these drugs can be integrated into existing treatment protocols to improve outcomes for patients with specific malignancies. Continued studies will provide insights into their mechanisms of action and potential benefits in oncology.

Features

BAV199 and BAV215 are monoclonal antibodies targeting the immune checkpoint protein PD-1, primarily used in cancer immunotherapy.
BAV199 is designed to enhance anti-tumor immune responses by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It has shown promise in preclinical and early-phase clinical trials, particularly in solid tumors.
BAV215 is a similar PD-1 inhibitor with a focus on improving the pharmacokinetic profile to enhance efficacy and reduce side effects. Both antibodies aim to revive T-cell activity against cancer cells, potentially leading to improved patient outcomes.
Both BAV199 and BAV215 are part of ongoing research to expand treatment options for various cancers, including melanoma, lung, and renal cell carcinomas. Their development is part of a broader strategy to harness the immune system in fighting cancer, showcasing the potential of checkpoint inhibitors in modern oncology.

Package

The BAV199 and BAV215 are typically available in a DO-41 (or similar) axial-lead package type. This cylindrical package design is suited for through-hole mounting and offers good thermal performance for these common signal diode applications.

Pinout

The BAV199 and BAV215 are dual Schottky barrier diodes, typically housed in a standard 8-pin plastic package.
### Pin Count:
- BAV199: 8 pins
- BAV215: 8 pins
### Pin Functions:
- Pin 1: Anode of Diode 1 (D1)
- Pin 2: Cathode of Diode 1 (D1)
- Pin 3: Anode of Diode 2 (D2)
- Pin 4: Cathode of Diode 2 (D2)
- Pin 5: Anode of Diode 1 (D1) (also connected to Pin 1)
- Pin 6: Cathode of Diode 1 (D1) (also connected to Pin 2)
- Pin 7: Anode of Diode 2 (D2) (also connected to Pin 3)
- Pin 8: Cathode of Diode 2 (D2) (also connected to Pin 4)
Both diodes are used for applications like switching, clamping, and rectification in various electronic circuits due to their low forward voltage drop and fast switching speed.

Manufacturer

The BAV199 and BAV215 are manufactured by BASF, a global chemical company headquartered in Ludwigshafen, Germany. BASF is one of the largest chemical producers in the world, specializing in a wide range of products, including chemicals, plastics, performance products, and agricultural solutions. The company is known for its commitment to innovation, sustainability, and research and development in various sectors such as automotive, electronics, and construction. BASF operates on a global scale, serving diverse industries and markets while focusing on creating solutions that address environmental challenges and improve quality of life.

Application

BAV199 and BAV215 are bispecific antibodies targeting cancer immunotherapy. BAV199 (targeting CD3 and HER2) is used for treating HER2-positive cancers, enhancing T-cell engagement to kill tumor cells. BAV215 (targeting CD3 and PD-L1) aims to disrupt the immune checkpoint, boosting T-cell activation and response against various tumors. Both are being explored in clinical trials for their efficacy and safety in oncology.

Equivalent

The BAV199 and BAV215 are dual switching diodes. Equivalent products include the 1N4148, 1N914, and BAT54 for the BAV199, and the 1N4001 or 1N5817 for the BAV215. Always check the specific electrical characteristics and packaging to ensure compatibility with your application.